...
首页> 外文期刊>Journal of pharmaceutical sciences. >Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent.
【24h】

Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent.

机译:使用(SBE)(7m)-β-环糊精作为增溶剂从羟丙基甲基纤维素基质片剂中控制和完全释放模型水溶性差的药物强的松龙。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Sustained-release formulations such as hydroxypropyl methylcellulose (HPMC)-based hydrophilic matrix tablets of poorly water-soluble drugs often result in incomplete release because of the poor solubility and dissolution rate of the drug in the hydrophilic matrix. Sulfobutylether-beta-cyclodextrins ((SBE)(7M)-beta-CDs) have been known to improve the solubility of such drugs by forming inclusion complexes. The present paper deals with the modification of drug release from an HPMC-based matrix tablet of a sparingly water-soluble drug, prednisolone (PDL), using (SBE)(7M)-beta-CD as a solubilizing agent. Tablets were prepared by direct compression of a physically mixed PDL, (SBE)(7M)-beta-CD, and polymer. On exposure to water, an in situ PDL:(SBE)(7M)-beta-CD complex was formed in the gel layer, and enhanced drug release relative to a control formulation was observed (lactose used as the excipient instead of (SBE)(7M)-beta-CD ). Other possible changes due to the incorporation of (SBE)(7M)-beta-CD in the formulation were also probed. Incorporation of (SBE)(7M)-beta-CD lead to a higher water uptake relative to the control (lactose) formulation. For a fixed total tablet weight, polymer type, and loading, the drug release rate appeared to depend on the molar ratio of (SBE)(7M)-beta-CD to PDL and not the absolute amount of (SBE)(7M)-beta-CD present in the matrix tablet. This work shows that incorporation of (SBE)(7M)-beta-CD into the matrix tablets could be considered in designing a sustained-release tablet of poorly water-soluble drugs.
机译:由于药物在亲水性基质中的溶解度和溶解度较差,因此缓释制剂(例如水溶性差的药物的羟丙基甲基纤维素(HPMC)基亲水性基质片剂)通常会导致释放不完全。已知磺基丁基醚-β-环糊精((SBE)(7M)-β-CDs)通过形成包合物来改善此类药物的溶解性。本文涉及使用(SBE)(7M)-β-CD作为增溶剂从微水溶性药物泼尼松龙(PDL)的基于HPMC的基质片剂中释放药物的方法。通过直接压缩物理混合的PDL,(SBE)(7M)-β-CD和聚合物制备片剂。暴露于水后,在凝胶层中形成原位PDL:(SBE)(7M)-β-CD复合物,并且观察到相对于对照制剂而言,药物释放增强(乳糖用作赋形剂而不是(SBE) (7M)-beta-CD)。还探讨了由于在配方中掺入(SBE)(7M)-β-CD而引起的其他可能的变化。相对于对照(乳糖)制剂,(SBE)(7M)-β-CD的引入导致更高的吸水率。对于固定的总片剂重量,聚合物类型和载量,药物释放速率似乎取决于(SBE)(7M)-β-CD与PDL的摩尔比,而不取决于(SBE)(7M)- β-CD存在于基质片剂中。这项工作表明,在设计水溶性差的药物缓释片剂时,可以考虑将(SBE)(7M)-β-CD掺入基质片剂中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号